News | October 3, 2017

Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares Combined Company will be Strongly Positioned to Bring Needed New Therapies to...

News | November 15, 2017

Arvinas Expands Strategic License Agreement with Genentech Expansion of 2015 agreement brings total deal value to potentially exceed $650 million NEW HAVEN, Conn., November 15, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on...

News | November 15, 2017

Jefferson Health Selects Kyruus’ Solutions to Support Its Expansion and Enhance Patient Access Growing Health System to Build Comprehensive Provider Directory and Optimize Patient-Provider Matching Boston, MA – Kyruus, a leader in provider search and scheduling...

News | November 09, 2017

SANOFI, PRINCIPIA AGREE TO DEVELOP MULTIPLE SCLEROSIS DRUG CANDIDATE Clinical-stage oral drug candidate (PRN2246) with the potential to treat multiple sclerosis Principia to receive $40 million upfront payment, future milestone payments could total $765 million...

News | October 9, 2017

Neuronetics Named 2017 Health Care Innovator by Philadelphia Business Journal Recognized for company’s breakthrough non-drug depression treatment, NeuroStar® Advanced Therapy Malvern, Pa., October 9, 2017 – Neuronetics, Inc., a privately held medical device company...

News | October 11, 2017

NeuroStar® Advanced Therapy Approved as a Life-Changing Depression Treatment to Help Conquer Depression in Japan Proven, breakthrough non-drug treatment provides safe and effective option to the country’s critical public health issue Proven, breakthrough...